Barclays Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $111 to $110.
August 06, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Biomarin Pharmaceutical but lowers the price target from $111 to $110.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100